XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

Roche

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: docetaxel; Drug: capecitabine

Study type: Observational

Funder types: Industry

Identifiers

NCT01777945

ML28505

Details and patient eligibility

About

This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.

Enrollment: 46 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants, >/= 18 years of age
• HER2-negative metastatic breast cancer
• Participants initiated on first-line therapy with Xeloda and docetaxel in accordance with the Summary of Product Characteristics; participants who started treatment with Xeloda and docetaxel no more than 3 months before enrollment in this study are also eligible

Exclusion criteria

• Contraindications to Xeloda treatment according to the Summary of Product Characteristics

Trial design

46 participants in 1 patient group

Participants Receiving Capecitabine/Docetaxel

Description:

Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.

Treatment:

Drug: docetaxel

Drug: capecitabine